Table 1 Baseline characteristics of the 101 patients with bone marrow metastatic neuroblastoma
Characteristic | Total [cases (%)] |
|---|---|
Age (months) | |
 < 18 | 16 (15.8) |
 ≥ 18 | 85 (84.2) |
Sex | |
 Male | 57 (56.4) |
 Female | 44 (43.6) |
WBC (× 109/L) | |
 > 10 | 17 (16.8) |
 4–10 | 60 (59.4) |
 < 4 | 24 (23.8) |
Hemoglobin (g/L) | |
 > 120 | 8 (7.9) |
 90–120 | 59 (58.4) |
 60–89 | 33 (32.7) |
 < 60 | 1 (1.0) |
Platelet (× 109/L) | |
 > 300 | 47 (46.5) |
 100–300 | 48 (47.5) |
 < 100 | 6 (6.0) |
Risk stratification | |
 Low-risk | 1 (1.0) |
 Intermediate-risk | 7 (6.9) |
 High-risk | 93 (92.1) |
Primary tumor site | |
 Abdomen | 88 (87.1) |
 Thorax | 12 (11.9) |
 Neck | 1 (1.0) |
11q23 deletion | |
 Yes | 40 (39.6) |
 No | 61 (60.4) |
MYCN amplification | |
 Yes | 12 (11.9) |
 No | 89 (88.1) |
LDH (IU/L) | |
 < 1500 | 79 (78.2) |
 ≥ 1500 | 22 (21.8) |
NSE (ng/mL) | |
 < 370 | 60 (59.4) |
 ≥ 370 | 41 (40.6) |
Event | |
 No event | 49 (48.5) |
 Relapse/progression | 13 (12.9) |
 Death | 39 (38.6) |